Cangene (FRA:YGE) Change In Receivables : €5.48 Mil (TTM As of Oct. 2013)

View and export this data going back to . Start your Free Trial

What is Cangene Change In Receivables?

Cangene's change in receivables for the quarter that ended in Oct. 2013 was €-3.51 Mil. It means Cangene's Accounts Receivable increased by €3.51 Mil from Jul. 2013 to Oct. 2013 .

Cangene's change in receivables for the fiscal year that ended in Jul. 2013 was €2.59 Mil. It means Cangene's Accounts Receivable declined by €2.59 Mil from Jul. 2012 to Jul. 2013 .

Cangene's Accounts Receivable for the quarter that ended in Oct. 2013 was €18.54 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Cangene's Days Sales Outstanding for the three months ended in Oct. 2013 was 93.77.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Cangene's liquidation value for the three months ended in Oct. 2013 was €-6.08 Mil.

Cangene Change In Receivables Historical Data

The historical data trend for Cangene's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cangene Change In Receivables Chart

Cangene Annual Data

Trend

Jul04

Jul05

Jul06

Jul07

Jul08

Jul09

Jul10

Jul11

Jul12

Jul13

Change In Receivables

Get a 7-Day Free Trial

1.52

2.47

-10.15

4.57

2.59

Cangene Quarterly Data
	Jan09	Apr09	Jul09	Oct09	Jan10	Apr10	Jul10	Oct10	Jan11	Apr11	Jul11	Oct11	Jan12	Apr12	Jul12	Oct12	Jan13	Apr13	Jul13	Oct13
Change In Receivables	Get a 7-Day Free Trial															-6.53	3.48	-4.56	10.08	-3.51

Cangene Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Oct. 2013 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.48 Mil.

Cangene (FRA:YGE) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Cangene's Days Sales Outstanding for the quarter that ended in Oct. 2013 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	18.541	/	18.043	*	91
=	93.77

2. In Ben Graham's calculation of liquidation value, Cangene's accounts receivable are only considered to be worth 75% of book value:

Cangene's liquidation value for the quarter that ended in Oct. 2013 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	28.361	-	68.269	+	0.75 * 18.541	+	0.5 * 39.846
=	-6.08

Cangene Change In Receivables Related Terms

Thank you for viewing the detailed overview of Cangene's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Cangene (FRA:YGE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cangene Corporation (FRA:YGE) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.cangene.com

Cangene Corporation is a fully integrated developer and manufacturer of immune therapeutics, primarily targeting infectious disease, hematology, transplantation and biodefense applications. The company manages its business and evaluate performance based on two operating segments: biopharmaceutical operations and contract services. Revenues are generated from product sales, and contract manufacturing and contract-R&D services.

Cangene (FRA:YGE) Headlines

No Headlines